title: The Cost and Value of Anti-Epidermal Growth Factor Receptor Therapies: Let's Not Be Rash.
authors.affiliation: Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
authors.forename: Leonard B
authors.initials: LB
authors.lastname: Saltz
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000191:economics; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000191:economics / Q000201:enzymology / Q000235:genetics / Q000401:mortality / Q000473:pathology; D003362:Cost-Benefit Analysis; D018572:Disease-Free Survival; D016527:Drug Costs; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000378:metabolism; D005076:Exanthema / Q000139:chemically induced* / Q000191:economics; D006801:Humans; D058990:Molecular Targeted Therapy; D009154:Mutation; D018579:Patient Selection; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000191:economics; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; C117307:KRAS protein, human; D047428:Protein Kinase Inhibitors; C512478:EGFR protein, human; D066246:ErbB Receptors; D016283:Proto-Oncogene Proteins p21(ras)